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Not everything is what it seems: malignant pleural mesothelioma 
mimicking lung cancer
Abstract
Malignant pleural mesothelioma usually arises from the pleural surface and progressively encases the lungs. Pulmonary involve-
ment generally occurs at an advanced stage, while intraparenchymal nodules, in the absence of pleural lesions, constitute a less 
frequent presentation. We describe the case of a patient with multiple bilateral pulmonary nodules, mediastinal lymphadenopa-
thies and left pleural effusion in the absence of pleural lesions, simulating advanced stage lung cancer. Thoracoscopic inspection 
did not detect any lesions. Pathological examination on one pulmonary nodule revealed malignant pleural mesothelioma. Despite 
its rarity, intraparenchymal malignant pleural mesothelioma should always be taken into account, when  lung nodules are present, 
to prevent misdiagnosis and avoid delayed treatment.
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Introduction
Malignant pleural mesothelioma (MPM) is a 
rare malignancy, arising from the pleural surface 
and progressively wrapping and constricting the 
lungs. Typical radiological findings are diffuse 
pleural thickenings or nodules, associated with 
pleural effusion, while pulmonary lesions usual-
ly occur later in the disease course [1]. Instead, 
intrapulmonary growth in the absence of pleural 
disease represents an uncommon mode of presen-
tation, as few examples are described in the lite-
rature. Here we report the case of a patient with 
multiple bilateral pulmonary nodules and left 
pleural effusion, in the absence of pleural lesions. 
Case report
A 67-year-old woman was admitted with 
dyspnoea on exertion and persistent cough. She 
had undergone combined chemo-radiotherapy 
plus splenectomy for a Hodgkin’s lymphoma and 
triple coronary bypass surgery for myocardial in-
farction with papillary muscle rupture. There was 
no relapse of lymphoma since the end of therapy, 
dating back thirty-seven years. Physical examina-
tion detected left hemithorax basal hypophonesis 
and diminished vesicular murmur. Computed 
tomography (CT) showed multiple bilateral pul-
monary nodules, left pleural effusion plus suba-
ortic and subcarinal lymph nodes enlargement. 
There was no radiological evidence of pleural 
thickening (Figure 1A). 18F-Fluoro-Deoxy-Gluco-
se Positron Emission Tomography (18F-FDG PET) 
revealed an increased uptake in the pulmonary 
nodules and mediastinal lymph nodes (Figure 
1B). Flexible bronchoscopy with endobronchial 
ultrasound-guided transbronchial needle aspira-
tion (EBUS-TBNA) was then carried out on the 
mediastinal hypermetabolic lymphadenopathies. 
Cytopathology disclosed an epithelioid malignan-
cy, suspicious of MPM. In order to rule out pleu-
ral involvement and to collect more specimens 
for differential diagnosis, thoracoscopic pleural 
biopsies were recommended. No suspicious le-
sions were found at pleural exploration. Pleural 
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fluid cytology revealed reactive mesothelial cells, 
granulocytes and lymphocytes. A tumorectomy of 
one pulmonary nodule of the left lower lobe was 
then performed. Histopathological examination 
revealed a nodule of inflammatory cells inter-
mingled with epithelioid atypical cells, isolated 
or arranged in microaggregates (Figure 2), with 
an immunohistochemical and molecular profile 
consistent with MPM. The neoplastic population 
was positive for epithelial markers (cytocheratin 
AE1/AE3 and cytcheratin 5/6), mesothelial mar-
kers (calretinin and WT-1) and negative for pul-
monary antibody (TTF-1) (Figure 3). The patient 
started chemotherapy with combined Cisplatin 
and Pemetrexed, but died two months later of 
acute drug toxicity after the first cycle.
Discussion
Intraparenchymal nodules in the absence of 
pleural lesions constitute a very rare presenta-
tion of MPM, with a prevalence of 0.6% [2]. Due 
to the rarity of this growth pattern, differential 
diagnosis represents a challenging issue. In the 
described case, multiple bilateral pulmonary 
nodules, mediastinal lymphadenopathies and 
left pleural effusion in a former smoker were 
suggestive of stage IV lung cancer [3]. On the 
other hand, pleural effusion might have resulted 
from cardiac dysfunction, given the patient’s 
clinical history. Unexpectedly, at thoracoscopic 
inspection no lesions were found on the pleural 
surface and, even more surprisingly, pathological 
examination on one pulmonary nodule revealed 
an intraparenchymal MPM. Prognosis of this 
unusual variety of MPM seems to be slightly 
better than the “classic” form, with a survival of 
28 months [2]. Our patient, unfortunately, died 
Figure 1. A. Computed tomography axial view showing multiple pul-
monary nodules (white arrows) associated with left pleural effusion 
(black asterisk). A total of 13 nodules were detected, 8 in the right lung 
and 5 in the left lung; B. 18F-Fluoro-Deoxy-Glucose positron emission 
tomography detecting an increased uptake in the pulmonary nodules 
(white asterisks) and mediastinal lymph nodes (white arrow). No 
pleural uptake was detected
Figure 2. Lung nodule composed of inflammatory cells intermingled with epithelioid cells that reveal cytological atypia (black arrows)
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two months after surgery, due to acute toxicity fol-
lowing the second chemotherapy cycle. However, 
the recognition of this rare variety of MPM and its 
distinction from lung cancer was fundamental in 
order to elaborate a therapeutic approach, as, for 
instance, chemotherapy regimens for MPM and 
lung cancer are different. In conclusion, despite 
its rarity, intraparenchymal MPM should always 
be taken into account when in the presence of 
lung nodules to prevent misdiagnosis and avoid 
delayed treatment.
Acknowledgements
The Authors’ contributions: E.P. drafted the 
manuscript. L.G. was responsible for the critical 
review of important intellectual content. C.R. 
provided radiological images and their inter-
pretation. M.G. was responsible for pathological 
analysis. L.S. was in charge of supervising the 
work as a whole. 
All Authors gave final approval of the ma-
nuscript.
Other contributions: The Authors would 
like to thank Maria Giovanna Campobasso for 
proofreading the text and Dr. Luca Bertolaccini 
for his precious advice.
Conflict of interest
None declared.
References:
1. Nind NR, Attanoos RL, Gibbs AR. Unusual intraparen-
chymal growth patterns of malignant pleural mesothelio-
ma. Histopathology. 2003; 42(2): 150–155, doi: 10.1046/j.
1365-2559.2003.01555.x, indexed in Pubmed: 12558747.
2.  Larsen BT, Klein JRH, Hornychová H, et al. Diffuse intra-
pulmonary malignant mesothelioma masquerading as inter-
stitial lung disease: a distinctive variant of mesothelioma. 
Am J Surg Pathol. 2013; 37(10): 1555–1564, doi: 10.1097/
PAS.0b013e3182910c82, indexed in Pubmed: 23797722.
3. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition 
Lung Cancer Stage Classification. Chest. 2017; 151(1): 193–
–203, doi: 10.1016/j.chest.2016.10.010, indexed in Pubmed: 
27780786.
Figure 3. Immunohistochemical profiling of the lesion disclosed po-
sitivity (brown staining) of the atypical cells for cytocheratin AE1/AE3 
(top left), WT1 (top right) and calretinin (bottom left), associated to 
negativity (absence of brown staining) for TTF1 (bottom right)
